A LTHOUGH a number of genes have been implicated .L\. in aging, in most cases it has proven exceptionally difficult to determine the physiological role, if any, that these genes play in the aging process. Progress in this area has been aided, however, by the recent development of powerful molecular genetic approaches. It is now possible, for example, to use a transgenic mouse model to overexpress or a gene knockout to underexpress (heterozygous null mutation) or completely inhibit the expression of a specific gene (homozygous null mutation) and to assess the effects of these manipulations on the aging process in an intact animal. On the other hand, because these genetic manipulations are in effect during embryonic development as well as throughout life, there are also significant limitations to the interpretation of the data obtained. Recent data, for example, clearly illustrate that the interpretation of a gene's function may be quite different if it is overexpressed throughout life, only during development, or only during postnatal life (1) . All too frequently, the genetically altered mouse simply dies, either before or shortly after birth. On other occasions, during the process of development, tile physiology of the mouse may adapt, often quite dramatically, to the altered genetic environment. This latter possibility is well exemplified by the apparently normal development of skeletal muscle which occurs following the knockout of MyoD, a key gene in muscle determination (2) . This unanticipated response appears to result from a compensatory developmental increase in Myf-5 expression (3). It is clear, therefore, that the normal physiological contribution of specific genes to complex lifelong processes, such as aging, may be difficult to define with the applica-B30 tion of conventional transgenic mouse or knockout mouse approaches alone.
Because of the limitations of these approaches, it would be extremely valuable in aging studies to have the capacity to exogenously regulate the level of activity of the gene of interest. With the use of a regulatable expression system, one could, for example, rescue an otherwise lethal gene knockout mouse during embryological development. If the affected gene were not essential for postnatal survival, its expression could be shut off postnatally, and the effects of the absence of the expression of this gene could be experimentally assessed. In this way it should be possible to dissect the role of a gene in postmaturational aging separately from its involvement in embryonic development. Even if the expression of the gene were essential for life, it might be possible to titrate its expression postnatally at a low level which is still compatible with life and to determine the effect of this muted level of expression on aging or longevity.
A regulatable promoter system also offers the potential for studying the effects of the overexpression of a gene at selected times during the life span. In principle, the gene could be introduced into the genome of the transgenic mouse where it would remain silent until induced to overexpress by the application of an exogenous inducer. With this approach, one could determine, for example, if longevity is affected when a selected DNA repair enzyme or a key enzyme involved in the defense against free radicals is overexpressed in a transgenic model but only during a defined period of the total life span.
Although traditionally a host of different inducible promoters have been used to drive transcriptionally linked loss of repressor protein binding and activation of the T' gene.
In the Tet-regulatable transactivator system, the first or "transactivator" construct consists of a strong gene promoter driving the expression of a synthetic transactivator protein (tTA) (13) (Figure lA) . The latter is a translational fusion of the coding sequence of the E. coli TnlO Tet repressor with the carboxy terminal 'domain of the Herpes simplex (HS) VP16 protein. The VP16 protein activates a number of mammalian gene promoters (17) , apparently by binding directly to key transcription factors involved in the formation of the RNA polymerase II preinitiation complex (18) (19) (20) (21) (22) . In initial applications, the transcription of the tTA mRNA was driven by a human cytomegalovirus (hCMV) promoter, but, subsequently, a number of different strong promoters have been used. In transgenic models, the choice of the promoter for the transactivator construct dictates the tissue distribution of expression of the Tet-regulatable expression system.
In the absence of Tet, the tTA protein (Figure lA) binds as a dimer (14, 23, 24) to a heptad of Tet operator sequences in the upstream region of a transactivator-dependent promoter (TD) located in the second or "reporter" construct. The binding of tTA to these operator sequences leads to the activation of TD, which in tum drives the expression of the transcriptionally linked gene, e.g., the E. coli~-galactosi- genes in mammalian cell lines, the nature of these systems and/or their inducing agents preclude their application to transgenic models for aging studies. The Escherichia coli lac repressor system, for example, has been utilized on a number of occasions to modulate the expression of a gene in mammalian cells (4) . However, the level of activation achieved is significantly limited by the toxicity of the inducer, isopropyl-Bvo-thlogalactopyranoside (IPTG) (5, 6) . Glucocorticoid-inducible promoters have also been used to drive the expression of transcriptionally linked genes in mammalian cells (7) . However, in whole animal models, glucocorticoids markedly enhance the expression of numerous endogenous genes which also have the potential to affect aging. Therefore, in a transgenic animal model, it would be difficult to separate the confounding effects that the glucocorticoid-mediated activation of these endogenous genes may have on the aging process from those exerted by a transgene whose activity was induced by the exogenous administration of this steroid hormone. A similar problem would occur if the metallothionein promoter were utilized to .drive the inducible expression of a gene which is suspected to have a significant role in the process of aging.
Because it is much less toxic than cadmium, zinc is usually employed as the exogenous inducer when the metallothionein promoter is employed as an inducible promoter in transgenic studies (8, 9) . However, zinc is also an important factor in a number of physiological processes which are potentially related to aging (10, 11) . Thus, in an animal, the effect exerted on aging by a fusion gene which was induced to express by the administration of zinc could not be totally resolved from the effects on aging of other endogenous genes or metabolic processes which are also modulated either directly or indirectly by this metal.
On the other hand, the last 5 years have seen the introduction of three new exogenously regulatable promoter systems which share the capacities to (i) drive a high level of expression of a transcriptionally linked gene, (ii) respond dramatically to nontoxic doses of regulators which exert few, if any, pleiotrophic effects on endogenous genes, and (iii) function compatibly with a transgenic mouse model. The purpose of this review is to consider the positive and negative features of each of these regulatable promoter systems with regard to their potential application to transgenic models for the study of aging. These systems were also briefly discussed in a more comprehensive recent review of genetic approaches to the conditional silencing of genes in mammalian models (12) .
TETRACYCLINE-REGULATABLE TRANSACTIVATOR SYSTEM

Repressible System (tTAr)
The tetracycline (Tetj-regulatable transactivator system employs two chimeric constructs to place a gene of interest under the control of a Tet-regulatable 'promoter (13) . The mechanism is based on the repressor protein which negatively regulates the expression of the Tet resistance gene (T") 'associated with the TnlO transposon "found in E. coli (14, 15) . In the absence of the antibiotic, this repressor suppresses the expression of the Tet resistance gene by binding to the Tet operator (16) . The introduction of Tet leads to a no expression Figure 1 . A diagrammatic illustration of the repressible tetracycline (Tet)-regulatable transactivator system. A, In the absence of Tet, the transactivator protein (tTAr protein) binds to the Tet operator sequences in the transactivator dependent promoter (TO) and induces the transcription of the 13-ga1actosidase reporter gene (13-gal) . B, In the presence of Tet, the binding of this antibiotic to the transactivator prevents the binding of the latter to the TO promoter and thus transcription of the 13-galactosidase gene is prevented. dase (13-gal) gene shown in Figures IA and B . However, when present, Tet binds with high affinity directly to tTA and induces allosteric changes, leading to at least a 1000-fold reduction in its binding affinity for the Tet operator sequences (14) . The net effect is a suppression of the expression of the gene which is driven by the TD promoter ( Figure 1B) . Because in this scheme the binding of Tet represses the function of the transactivator protein, it shall be abbreviated hereafter as tTAr.
Initial studies showed that the stable introduction of the Tet-regulatable system into He1a cells produced a highly efficient Tet-mediated regulation of the activity of the tTArdependent promoter. The activation of the TD promoter, as evidenced by the expression of a luciferase reporter, was modulated over as much as five orders of magnitude by progressively higher dosages of Tet (13) . This observation showed that at least in cultured cells, it is possible to regulate the level of activity of the transcriptionally linked gene by changing the dosage of the antibiotic in the medium. Luciferase reporter activity was virtually completely repressed at concentrations of Tet roughly 1110 of the nontoxic, therapeutic dosage. In a similar application, tTAr induced the expression of a partial 13-amyloid precursor protein in SK-N-MC neuroblastoma cells, and this expression was essentially totally repressed by the addition of 1 ug/ml, Tet (25) . In Rat-2 fibroblasts, the overexpression of the E2F-I protein, which was driven by the tTAr system, promoted S-phase entry and subsequent apoptosis (26) . Significantly, the level of apoptosis activated in this system was inversely dependent on Tet dose.
The Tet-responsive system also worked effectively following its introduction into tissue cells of an intact animal. For example, tTAr activated the transcription of a luciferase reporter by over 100-fold in cardiac myocytes following the injection of the Tet-responsive system into the ventricular musculature of rats. Further, this activation was repressed by 90% or 97% by the oral administration of 0.1 or 1 mg/mL Tet, respectively. Similar results were observed when the Tet-responsive binary expression system was introduced into skeletal muscle (28) .
In a transgenic mouse study, the hCMV promoter drove the expression of tTAr in some but not all tissues of transgenic mice (29) . The tTAr-mediated activation of the 13-galactosidase reporter gene was repressible by Tet to a background level of activity no greater than that observed in transgenic lines which did not carry the tTAr construct ( Figure 2 ). Further, this suppression was effected at a dosage of the antibiotic which had no demonstrable toxic effects on the adult transgenic mice or on fetal development. This latter observation illustrates an additional advantage of the Tet-responsive system: namely, that mammalian cells possess few, if any, functional Tet operator sequences. Therefore, unlike some other models involving the regulation of genes by inducible promoters, there are no detectable pleiotrophic effects of this antibiotic on endogenous mammalian genes.
In a subsequent transgenic study (30) , the tTAr system was used to drive the expression of SV40 large T antigen (TAg) in the submandibular gland. The expression of TAg, in tum, induced a progressive hyperproliferation of the striated ducts in this tissue. TAg overexpression was repressed by the subcutaneous implantation of slow release Tet pellets (Innovative Research of America, Toledo, OH). Interestingly, the hyperproliferation of the striated ducts was reversible if Tet was administered after 4 months but not after 7 months of TAg expression.
In a third transgenic study, the calcium-calmodulin dependent protein kinase II (CaMKII) promoter was employed to overexpress tTAr in the striatum and amygdala (31) . When these founders were mated to transgenic mice in which the coding sequence for CaMKII was linked to the TD promoter, a sevenfold overexpression of CaMKII was observed in the striatum and amygdala of doubly transgenic offspring. When compared to wild-type controls, these transgenic mice also showed a marked impairment of fear conditioning behavior. However, treatment of these transgenic animals with doxycycline, a more potent analogue of Tet, reversed the overexpression of CaMKII in the above brain regions and prevented the impairment of fear conditioning.
Tissue-specific promoters can also drive the transcription of tTAr in transgenic animals. When activated by a rat alpha myosin heavy chain promoter, tTAr was expressed in the heart but not in other tissues (32) . The transactivator, in tum, induced the heart-specific expression of the Id1 gene, and this effect was completely repressed by Tet administration. In a second study, the rat insulin promoter was used to drive the expression of tTAr specifically in pancreatic 13 cells of transgenic mice (33) . When these mice were bred to founders carrying a chimeric gene in which the TD promoter was linked to the TAg protein, 13 cell-specific tumors developed in the doubly transgenic offspring. These tumors showed growth arrest in the presence of Tet but proliferated upon its withdrawal. 
Inducible System (tTAi)
The Tet-responsive system has been recently modified by a mutation, which converts the tTA protein from a Tetrepressible to a Tet-inducible transactivator (34) . This inducible system was labeled the reverse Tet repressor (rTetR) by its originators but will be subsequently referred to as the Tet-inducible transactivator (tTAi) in this review. Schematically, the tTAi shares many of the features of the Tetrepressible system ( Figure 3) . However, in a major mechanistic departure from the repressible system, tTAi, in the absence of Tet, shows comparatively little binding to the Tet operator sequences located in the upstream region of the TD promoter. On the other hand, when Tet or one of its analogues binds to tTAi, steric changes are induced which markedly enhance its binding affinity for the Tet operator ( Figure 3 ). Therefore, in the tTAi system, Tet activates, rather than represses, the expression of the gene, which is transcriptionally linked to the TD promoter.
Following the stable transfection of Hela cells with the tTAi system, Tet induced the activity of a luciferase reporter in these cultured cells by 10-fold. Two analogues of Tet, doxycycline or anhydrotetracycline, which show a greater binding affinity than Tet for the transactivator protein (23), were even more effective, as they induced this reporter in a dose-dependent fashion up to 1000-fold (34) .
One recently published study suggests that the tTAi-regulatable system may show leaky expression in the absence of the Tet inducer (35) . On the other hand, other studies indicate that in the absence of its doxycycline inducer, the tTAi system shows little, if any, evidence of background expression in transgenic mouse models. Following 1 week of the administration of 2 mg/mL doxycycline in the drinking water, luciferase levels in tissues of doubly transgenic mice (hCMV-tTAilTD-luciferase) were elevated by three to five orders of magnitude over that observed in comparable animals which were not treated with this antibiotic (36) . The tissue distribution of the expression of the reporter enzyme was consistent with that previously observed when the hCMV promoter was used to drive the expression of the transactivator (29) . Importantly, in the absence of doxycycline, although a low level of luciferase expression was strong promoter I tTAigene observed in some tissues, this expression was reported to be no greater than that observed in mice which were transgenic for the TD-Iuciferase construct alone.
In a separate study, the expression of tTAi was driven in a tissue-specific manner by the Clara cell 10 kilodalton protein (CCI0) promoter which directed the expression of this inducible transactivator to the epithelium of the conducting system of the lung (1) . In this study, the TD promoter in the reporter construct was linked to a human interleukin-ll (lL-ll) eDNA. As in the preceding study, only marginally detectable human IL-ll mRNA or protein was observed in the lungs of doubly transgenic mice in the absence of doxycycline treatment. However, a greater than sevenfold increase in IL-ll was observed in the lungs of doubly transgenic mice within 6 days following the provision of 0.5 mg/mL doxycycline in the drinking water. No doxycyclinemediated induction of human IL-l1 was observed in any other tissues of these animals. Interestingly, the induction of IL-ll expression was observed in the lungs of new born pups whose mothers had been provided with doxycycline in the drinking water during gestation or in nursing pups whose mothers were provided with the antibiotic following parturition. These latter results clearly show that doxycycline is able to cross the placental barrier or to be secreted into the milk in sufficient quantities to induce the tTAi transactivator.
The cumulative results of these two studies suggest that the leakiness of the tTAi, which has been suggested by studies in some cells lines, may not be physiologically significant in vivo.
RU486-INDUCIBLE TRANSACTIVATOR SYSTEM
The RU486 inducible system also employs a binary strategy. As with the Tet-regulatable systems, the transactivator construct utilizes a strong promoter to drive the transcription of the transactivator protein (GL-VP) (37) . In this strategy, however, GL-VP is a fusion protein consisting of the coding sequence of the yeast GAL4 transactivator protein, which is linked at its carboxy terminal end to the coding sequence of a truncated ligand-binding domain of the human progesterone receptor. The mutated human progesterone receptor domain manifests a high affinity binding capacity for RU486 as well as other synthetic progesterone receptor antagonists but retains no demonstrable capacity to bind progesterone or any related endogenous steroidal hormones. The GAU transactivator region contributes a DNA binding activity as well as a dimerization function and a nuclear localization signal to the chimeric construct. Because mammalian DNA is not believed to contain functional GAL4 DNA-binding elements, the use of a GAU DNA-binding domain also reduces the probability that the functional transactivator will activate endogenous mammalian genes. In addition, the GAL4 domain is linked at its amino terminal end to the same VP16 transactivator utilized in the construction of the tTAr. The VP16 sequence is essential for functional transactivator activity in mammalian cells (37) .
In the presence of RU486, the GL-VP translational product dimerizes to form a functional trans-acting complex, which binds with high affinity to four 17-base pair GAL4-binding elements located 5' to the thymidine kinase (tk) promoter (pI7x4-tk) on the reporter construct, the second component of the RU486 binary system (Figure 4) . The binding of the complex to these elements activates the tk promoter, which in tum initiates the expression of a transcriptionally linked sequence (chloramphenicol acetyltransferase [CAT] in Figure 4) .
In an early test of the efficacy of the RU486-inducible system, CV-I cells were cotransfected with a transactivator construct in which GL-VP was driven by the hCMV promoter, and a reporter construct in which the coding sequence for CAT was transcriptionally linked to the pI7x4-tk promoter (37) . Although the tk promoter induced some baseline expression of CAT in the absence of RU486, up to a 20-fold increase in the activity of this reporter was observed following the administration of RU486. Subsequent studies showed that maximal activation of the p17x4-tk promoter occurred following the administration of 1 nM RU486, a concentration roughly one thousandth of the dose required for this compound to act as a progesteroneantagonist. By comparison, progesterone agonists or progesterone itself were ineffective in enhancing CAT expression. When the tk promoter in the reporter construct was replaced by an EIB gene TATA sequence (pI7x4-TATA), the baseline expression of CAT was significantly reduced. As a consequence, a more than 50-fold enhancement of CAT activity was observed in response to RU486 administration, but the overall magnitude of the expression of CAT was less than that observed with the pl7x4-tk promoter.
The RU486-inducible system has also been tested in a transgenic model. In these experiments, the coding sequence for the GL-VP transactivator was linked to a liverspecific transthyretin promoter. In order to obtain transgenic founders, which expressed the GL-VP transactivator, it was necessary to flank the chimeric construct with insulator sequences from the chick~-globin gene (38) . A second group of transgenic mice was developed in which the coding sequence for human growth hormone (hGH) was transcriptionally linked to the pI7x4-tk promoter. Doubly transgenic offspring were obtained by mating these two separate types of transgenic mice. The oral administration of RU486 to doubly transgenic mice induced a dose-related and a liver-specific expression of hGH, but no hGH was detectable in comparable transgenic mice in the absence of this inducer. The intraperitoneal administration of RU486 every other day for 17 days induced a greater than 50 percent increase in body weight of doubly transgenic mice ( Figure  5 ). By comparison, the body weights of doubly transgenic mice, which received only the drug vehicle, were not different from those of mice, which were transgenic for either the GL-VP transactivator construct or the p17x4-tk-hGH reporter construct alone. RU486 administration also had no effect on the body weights of mice which were transgenic for one or the other, but not both, of the chimeric constructs. Collectively, these observations suggest that (i) the RU486-inducible system can work very effectively in transgenic models and (ii) the leakiness of the p17x4-tk promoter, which was suggested from earlier studies in cell lines, may not be of physiological consequence, at least in some transgenic models.
ECDYSONE-INDUCIBLE TRANSACTIVATOR SYSTEM
The third approach to effect the regulatable activation of genes in mammalian cells and transgenic mouse models is based on the mechanism through which ecdysone induces metamorphosis in Drosophila (35) . This induction is mediated through an interaction of this steroidal hormone with a functional receptor formed by a heterodimerization of the ecdysone receptor with the protein product of the ultraspiracle gene. Unlike the two previous systems, the ecdysone-inducible system employs three chimeric constructs. The first utilizes a strong promoter to drive the transcription of the ecdysone receptor (VP-EcR, Figure 6 ). In Biogenic + RU Biogenic + Oil - Figure 4 . An illustration of the RU486-inducible transactivator system. A strong promoter is used to drive the expression of the GL-VP protein.
In the presence of RU486, the GL-VP protein forms a dimer and, in a complex with RU486, binds to elements upstream of the reporter construct to activate the thymidine kinase promoter (tk). The activation of tk in tum drives the expression of the chloramphenicol acetyltransferase (CAT) gene. 
_____~• ••GL-VP
CAT gene protein Figure 6 . A diagrammatic illustration of the ecdysone-inducible promoter system. A powerful promoter is used to drive the expression of the ecdysone receptor (VP-EcR) and the retinoid X receptor, separately. In the presence of ecdysone, these receptors heterodimerize in a complex with the steroid hormone and then bind to modified ecdysone-receptor binding sites upstream of a minimal promoter in the reporter construct. This binding induces the transcription of a transcriptionally linked reporter (in this case luciferase).
order to enhance the transactivational activity of the modified receptor, the transactivator region of the ecdysone receptor has been replaced with the corresponding domain of the glucocorticoid receptor, and a VP16 transactivator sequence has been attached to the truncated N-terminal end of this modified receptor. The second construct employs a strong promoter, potentially the same as that used for construct 1, to drive the expression of the retinoid X receptor (RXR), the mammalian homologue of the product of the ultraspiracle gene.
In the presence of ecdysone or muristerone A, its synthetic analogue, the translational products of constructs 1 and 2 heterodimerize and bind to four modified ecdysone receptor (EcR)-binding elements located 5' to a minimal promoter located on the reporter construct. The binding to these elements activates the minimal promoter, which in tum induces expression of the transcriptionally linked gene (luciferase in Figure 6 ). The tissue distribution of expression of the inducible gene is controlled by the choice of promoters used to drive the expression of the modified ecdysone and retinoid X receptors.
When the ecdysone-inducible system was transiently transfected into CV-1 cells, the basal expression of the luciferase gene, which was linked to the minimal promoter on the reporter construct, was 500-fold lower than that observed for the same reporter linked to the Tet-inducible (tTAi) system, which was also transiently transfected into the same cell line (35) . Exposure to 1~muristerone A induced a nearly 1000-fold increase in luciferase activity in the cells transfected with the ecdysone-inducible system. By comparison, due to a high level of baseline expression of luciferase in the CV-1 cells that were transfected with the tTAi system, only a 2.5-fold increase in luciferase activity was induced by treatment with 1 ug/ml, doxycycline. In N13 cells that were stably transfected with the ecdysoneinducible system, the response to ecdysone was shown to be both dose and time dependent
The ecdysone-inducible system has also been introduced --+ luciferase into transgenic mice (35) . A thymus-specific CD3 promoter was utilized to drive the expression of both the ecdysone and the retinoid X receptors, and a 13-gal reporter gene was transcriptionally linked to the minimal promoter in the reporter construct. In the absence of muristerone A administration, there was no detectable expression of the reporter gene in the brain, liver, or thymus of mice which were transgenic for all three constructs. However, following treatment with 10 mg of muristerone A, expression of the 13-gal reporter mRNA was induced in a tissue-specific manner in the thymus of the transgenic mice. This dosage of muristerone A had no observable behavioral effects on the transgenic animals.
TRANSREPRESSOR SYSTEMS
A novel regulatable transcription system was recently designed by linking the Kriippel-associated box (KRAB) repressor domain to the Tet repressor (39) . This KRAB domain is a highly conserved and potent transcriptional repressor found in the amino terminal region of approximately one third of all known human zinc finger proteins (40, 41) . The unusual aspect of this approach is that the fusion protein acts as a transrepressor rather than a transactivator. The mechanism of action of the KRAB domain is unknown, but is hypothesized to involve either an interference with the assembly of the transcription initiation complex or an alteration of the chromatin structure (39) . The regulatable system uses a strong promoter, usually hCMV, to drive the transcription of the transrepressor gene. The transrepressor protein binds to Tet operator sequences on a second reporter construct. Unlike the case in previously discussed systems, the binding of the transrepressor silences the activity of a strong promoter, for example, the hCMV or the Herpes simplex tk promoter, which would otherwise drive a high level of expression of the gene which is transcriptionally linked to this promoter in the reporter construct. In the presence of Tet, the binding of the transrepressor is prevented and the silencing effect on transcription is removed.
In Hela cells stably transfected with both constructs, only a low level of expression of the luciferase reporter was observed in the absence of Tet (39) . However, reporter expression was increased by 10-fold within 24 hours and by 50-fold within 72 hours after the administration of 0.5 ug/ml, Tet. The repressor activity of the KRAB sequence was demonstrable whether the Tet operator sequences were inserted 0.7 or 3.6 kilobases upstream of the transcription start site for the strong promoter.
Replacing the VP16 transactivator domain in the RU486-inducible system with a KRAB repressor domain (42) has also developed a similar transrepressor scheme. However, neither the Tet-transrepressor nor the RU486-transrepressor system has been tested in a transgenic model.
Potential Applications and Limitations
There are many positive features which support the application of the Tet-regulatable system to the develop- ment of transgenic models to study the role of specific genes in the process of aging. The Tet-repressible system, in particular, has been employed quite effectively to drive the expression of transcriptionally linked genes in a number of transgenic models. In each case, the expression of these genes was repressible by the administration of Tet or one of its analogues. Effective dosages of these compounds have been administered either in the drinking water (28, 31) or in slow-release pellets (29, 33) . With these routes of administration, Tet has also been shown to repress transcriptionally linked genes, which are expressed in the brain (31) . However, some results indicate that the repression induced by Tet is less efficient for genes expressing in the brain than in peripheral tissues (43) , perhaps reflecting an impaired capacity of the drug to cross the blood-brain barrier. This problem may be addressable, however, with the use of more lipophilic derivatives of Tet, e.g., minocycline or doxycycline (44) . At the doses required to effectively inhibit the expression of transcriptionally linked genes, Tet or its analogues appear to have few, if any, untoward influences on either the embryonic development or the physiology of the animal. In one case, however, treatment of mice with doxycycline (1 mg/mL) during development was reported to cause an impairment of adult spatial memory and memory of fear conditioning (31) . With respect to aging, the Tet-repressible system is ideally suited for experimental designs where a continuous activation of a gene of interest is desired except for a specific interval of the life span. One might wish, for example, to overexpress a glucose-transporter gene in a transgenic mouse model in order to look at the effects of reduced blood glucose on life span. To avoid the potentially confounding effect of hypoglycemia on brain development, this transporter gene could be linked to the TD promoter in the Tet-repressible system, and the administration of Tet could be used to prevent the overexpression of the transporter in the embryo and during early postnatal development. Following the completion of the maturation of the brain, Tet could be removed and the subsequent effects of the overexpression of the gene on blood glucose and on life span could be experimentally assessed.
The Tet-repressible system could also be applied if one wished to rescue an embryonically lethal knockout in order to assess the effects of the absence of the expression of this gene on longevity. For example, one of the ongoing projects in the Richardson laboratory is to use a mouse model with a homozygous null mutation in the (3-polymerase «(3-pol") gene (45) to test (i) whether there is an age-related accumulation of DNA damage in this model and (ii) if this accumulation has an influence on longevity. Evidence from others (46) show that cells from (3-pol-'-animals show a deficiency in base excision repair measured in vitro. Because the homozygous (3-pol null mutation is lethal during embryonic development, the plan is to utilize the Tetregulatable promoter system to rescue this mutation during embryonic development and then to either completely shut off the gene or, if necessary, to titrate a low level of postnatal expression of (3-pol. If the Tet-repressible system were employed in this particular application, it would necessitate the continued administration of Tet throughout the remaining life time of the animal. Because longevity studies in mice may extend for 36 months or more, such a long interval of administration presents the potential for cumulative toxic effects of even low dosages of this antibiotic. At the same time, it should be noted that no obvious evidence of toxicity or carcinogeneity was observed when either F344/N rats or B6C3Fl mice were treated up to 103 weeks with low dosages of this antibiotic (47) .
An obvious alternative approach for this particular experimental design is to utilize the Tet-inducible rather than the Tet-repressible system. Because Tet administration would only be required when the gene is to be activated, the overall exposure of the animal to this antibiotic would be minimized. As noted earlier, although there may be some background level of expression of the transcriptionally linked gene in association with the tTAi system (35), its appears not to be of physiological significance, at least in existing transgenic models (1, 36) . On the other hand, if the tTAi approach should lead to a low level of leaky expression, it might be used to advantage in some transgenic models (the (3-pol-/-rescue may be an example) in which the rescue of a lethal gene knockout requires a low level of expression of the gene throughout life.
The Tet-inducible transactivator system could also be used to assess the effects of the overexpression of DNA repair enzymes at selected stages of the life cycle. It would be of interest, for example, to assess the effects on the life span or age-related pathologies if a selected DNA repairrelated enzyme were overexpressed in a transgenic model (i) from birth, (ii) beginning at midlife, or (iii) only during the later stages of life.
The oxidative stress hypothesis remains one of the more plausible explanations for the phenomenon of aging (48) . Based on the examples just given, it is easy to conceive the possibilities for using the Tet-regulatable promoter systems to test the oxidative stress hypothesis by overexpressing enzymes involved in antioxidant defense systems during selected stages of the life span. In a different approach, the homozygous knockout of the manganese superoxide dismutase (Mn 2+SOD) gene, for example, is lethal within a few days following birth (49) . Therefore, just as in the case with the (3-pol homozygous knockout, the tTAi system could be used to rescue the Mn 2+SOD knockout and test the effects of the low postnatal expression of this enzyme on the accumulation of oxidative damage and on longevity. With the tTAr system and this same knockout model, reasonably physiological levels of Mn 2+SOD activity could be maintained for various lengths of the life span and then Tet could be administered to markedly reduce or completely inhibit the expression of this enzyme. The combined effects of age and the reduction or loss of Mn 2+SOD activity on pathology and/or longevity could be assessed.
The RU486-inducible system offers an alternative approach to aging studies in which a high level of activation of a gene is desired but for only a limited interval during the life span. Although the pl7x4-tk promoter appears to induce leaky expression of the transcriptionally linked gene in cultured cells (37) , this may also be of little physiological consequence in an intact animal (38) . RU486 is also lipophilic, which suggests that this inducer system may be suitable for use in the regulation of gene expression in the central nervous system (50) . In addition, recent modifications in the RU486 system (42) have focused on improving the level of inducibility of the p 17x4-TATA promoter, which shows less background expression in the absence of RU486 than does the p17x4-tk promoter (37) . However, the effects of these modifications on the function of the RU486 system in a transgenic model have not been reported. Reservations to the application of this system to studies of aging relate to the limited experience with its use in transgenic models and the lack of information as to the consequences of the long-term administration of even low dosages of RU486 on endogenous genes as well as on survival and life span.
The ecdysone-inducible system also appears to offer the potential to significantly activate a transcriptionally linked gene in the absence of a detectable background. However, when compared to either the Tet-or the RU486-regulatable promoter systems, the ecdysone-inducible system is somewhat more cumbersome to assemble in a transgenic model, as three .chimeric genes, rather than two, are required. In addition, although the results look promising, there is still only limited literature on the application of this system in transgenic mouse models. Cost, however, may be the most important practical limitation to the use of the ecdysoneinducible system in transgenic models of aging. In the only published study (35) , 10 mg of muristerone was utilized to induce the tissue-specific expression of a l3-gal reporter gene in a transgenic mouse model. Because a typical 1998 list price is $160 for 25 mg of this compound, it would be very expensive to employ this approach to induce even a limited expression of a gene in an aging animal model.
The transrepressor approaches may also offer a solution to the concerns about the cumulative toxicity of even low doses of either Tet or RU486 when they are administered over long time periods. These approaches could also be applied to experimental designs where one wishes to prevent the effects of the overexpression of a gene on embryological development or to look at the effects of the reduced expression of a gene at some other specified time during the life span. On the other hand, although the data look favorable, the function of these transrepressor systems have not been extensively studied even in cultured cells lines. This is particularly the case for the RU486-transrepressor system. Among the concerns is a continued low level of activity of the. promoter in the presence of transrepressor binding. Further, although it remains potent, the suppression of transcription appears to decrease the farther the binding site for the transrepressor is from the transcription start site of the transcriptionally' linked gene (39) . It is also unclear how efficiently the transrepressor system will switch on and off when introduced into complex promoters, particularly those which show cell typespecific expression. In addition to further characterization in cell lines, the applicability of the Tet-or the RU486-transrepressor systems to whole animal models of aging must also await evaluation of their functionality in transgenic models. It is unknown, for example, if high levels of expression ofKRAB may have effects' on endogenous genes.
'
Choice of Promoters
The key to the distribution of expression of any of the exogenously regulatable promoter systems is the choice of the promoter for driving the expression of the transactivator construct. Many of the genes, which are anticipated to play a role in aging, show expression in a wide distribution of tissues. Further, in order to effect expression of these genes over several orders of magnitude, it is preferable that the promoter used is capable of driving a high level of transcription of the transactivator or transrepressor mRNA. Therefore, for many aging-related applications, one would prefer to use a promoter which shows a high level and a broad distribution of expression. Although the hCMV promoter has been utilized to successfully express tTAr in a number of cell lines, its use has proven only moderately successful in transgenic mice (29) . In transgenic animals, the hCMV promoter produced a very high to moderate level of expression of tTAr in the tongue, thigh muscle, skin, spleen, and seminal vesicle, but little or no expression of this transactivator was detectable in other tissues. This heterogeneous expression pattern correlates closely with the tissue-distribution of congenital hCMV infections and therefore may reflect an unanticipated tissue specificity for the activation of the hCMV promoter in vivo (52, 53) .
One of the interesting possibilities is the ubiquitin C promoter which is reported to drive a high level of expression of transcriptionally linked genes and in a wide variety of tissues (54) . Others include the promoter for the rat CIEBPI3 gene (55) which has been shown to drive the expression of a cDNA in many tissues of transgenic mice (56) , or the promoter for the gene for murine 3-phosphoglycerate kinase (Pgk-l), a key enzyme in the glycolytic pathway and a cofactor for DNA polymerase ex. This latter gene is believed to be activated in all cells except spermatogenic cells (57) , and its promoter has been shown to drive the expression of heterogeneous cDNAs in a number of tissues of transgenic mice beginning at an early blastocyst stage of development (57, 58) . The retinoblastoma susceptibility (Rb) gene promoter is also believed to activate in most, if not all, tissues (59) . However, its activity may be low in some adult tissues, notably the liver and the heart (60).
Transactivator expression can also be selectively localized to specific organs or tissues by a growing list of tissuespecific promoters. The synapsin I promoter, for example, has been used successfully to direct brain-and spinal cordspecific expression (61, 62) , whereas the hepatotrophic hepatitis B virus (54), mouse major urinary protein (63), albumin (63) , and the transthyretin promoters (38, 64, 65) have all been used to direct expression of reporter genes to the liver. As noted earlier, the insulin promoter has been successfully utilized to target heterogeneous gene expression to pancreatic 13 islet cells (33) .
Strategies for Generating Transgene Models
The traditional approach for introducing any of the regulatable promoter systems into a transgenic model is to initially prepare separate founder lines, which carry either the transactivator or the reporter assembly. This approach has the important advantage of permitting a preselection of those founders, which show a high and preferred tissue dis-tribution of expression of the transactivator. Doubly transgenic mice are obtained by the subsequent mating of founder mice, which carry the transactivator with those that carry the reporter construct. If the transactivator and the reporter lines are each first bred to homozygosity, then all of the F1 offspring of matings between these lines will be hemizygous for both the transactivator and the reporter construct. Alternatively, if hemizygous transactivator and reporter lines are mated, one fourth of the offspring will be hemizygous for both constructs. With either strategy, the identification of doubly transgenic animals is straightforward. However, subsequent matings between FI offspring of these crosses are not recommended, as the transactivator and the reporter constructs are probably incorporated into separate chromosomes or at least significant distances apart on the same chromosome and thus may become segregated in offspring of FI crosses.
Recently, both the transactivator and the reporter complexes were incorporated into the same plasmid (CombitTA) and used to generate transgenic mice in which the expression of a luciferase reporter was under the control of the Tet-repressible system (43) . In that study, the CombitTA system was reported to induce a higher level of expression of the luciferase reporter than was observed when the transactivator and the reporter constructs were first introduced into separate founders. The repression of the activity of the luciferase reporter was also reported to be greater when slow-release pellets were employed than when Tet (1 mg/mL) was provided in the drinking water.
A frequently mentioned concern with the application of any of these regulatable promoter systems is that all three utilize the VPI6-transactivator domain in order to drive the gene of interest. The major reason that this system works is that the VPI6 domain binds exceptionally well to several of the critical factors involved in the assembly of the transcription preinitiation complex. Therefore, the high expression of the transactivator opens up the possibility that it may sequester a possibly limited supply of one or more transcription initiation factors within the cell and thus may potentially squelch the expression of some endogenous genes. Although the available evidence suggests that this has not been a problem, it could become significant at some time during the life span of a transgenic mouse. This particular concern has been considered in one novel modification of the Tet-repressible model in which the expression of tTAr was itself placed under the control of the TD promoter (66) . The appealing feature of this strategy is that the expression of the transactivator as well as the transcriptionally linked gene are both suppressed by the application of Tet, thus limiting the exposure of cells to the potentially toxic effects of the VPI6 protein. Transgenic animals have been produced which express this system, and the expression of tTAr has been shown to be regulatable by the administration of Tet. The limitations are that expression is not uniform across tissues. In addition, tissue-specific expression of the transactivator is precluded. Further, in transgenic animals the level of expression of the reporter is significantly lower than that observed in cell lines (67) .
A promising long-term solution to the potentially confounding effects of VPI6-mediated sequestration of important general transcriptional factors is offered by the recent development of a new generation of transactivator sequences which encode one or multiple copies of the minimalI2-amino acid transcriptional activation domain of the VPI6 protein (68) . Some of these bioengineered constructs lead to the expression of transactivators which show enhanced capacity to activate the reporter construct concomitant with a reduced potential for the squelching of endogenous genes.
Some concerns remain and, as may be anticipated with any model, there may be limitations to their application. However, the new generation of exogenously regulatable expression systems offer some exciting and unique tools which may be applied to the dissection the role of specific genes in the process of aging.
